Management of regorafenib-related toxicities: a review - PMC Video abstract of review paper "Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or Colorectal Cancer: Dosing Strategies With Regorafenib
Dr. Daniele on Impact of Regorafenib in HCC John L. Marshall, MD; Mohamed E. Salem, MD; and Monica Chacha, RN, highlight patient follow-up with regorafenib in colorectal Dr. Kim Reviews Studies Investigating Regorafenib in mCRC
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School Common side effects · Increased risk of getting an infection · Breathlessness and looking pale · Bruising, bleeding gums or nosebleeds · Tiredness and weakness ( Regorafenib in Advanced HCC
STIVARGA (Regorafenib) can have some serious side effects. Minimize the side Dosing of STIVARGA Side Effects of Oral Liver Cancer Therapies
John L. Marshall, MD; Mohamed E. Salem, MD; and Monica Chacha, RN, discuss overall clinical experience with treatments for Anthony El-Khoueiry, MD, discusses the use of regorafenib in a 63-year-old patient with hepatocellular carcinoma following Regorafenib (Stivarga®) | Macmillan Cancer Support
Anthony El-Khoueiry, MD, shares his expertise regarding treatment response and side effect management with regorafenib in a Panelists John L. Marshall, MD; Cathy Eng, MD; Daniel G. Haller, MD; Tara E. Seery, MD; and Tanios-Bekaii Saab, MD; outline
Regorafenib (oral route) - Side effects & dosage - Mayo Clinic What Are the Side Effects? | STIVARGA® (regorafenib) Patient
More common · Bleeding gums · bloody or cloudy urine · blurred vision · cough or hoarseness · coughing up blood · difficult, burning, or painful urination Optimal Dosing of Regorafenib in Colorectal Cancer Managing Toxicities Associated With Regorafenib
John L. Marshall, MD; Mohamed E. Salem, MD; and Monica Chacha, RN, provide education regarding the efficacy, safety, Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a
The most serious side effects with STIVARGA are: Serious liver problems, Infection, STIVARGA may lead to a higher risk of infections especially of the urinary The most common grade 3–4 adverse reactions with the drug are hand foot skin reactions (HFSR), diarrhea, hypertension and fatigue. Regorafenib in refractory biliary tract cancer
When You Have Decided to Prescribe Regorafenib Regorafenib: MedlinePlus Drug Information Tanios Bekaii-Saab, MD, and Johanna C. Bendell, MD, evaluate the ReDOS trial and explain its impact on dosing approaches
Filmed on location in New York during the Great Debates and Updates in GI Malignancies 2015, this webcast is part of a series Alan Venook, MD relays the optimal dose for regorafenib (Stivarga) in the 2nd line treatment of mCRC
Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses results of a Phase I/IB study of regorafenib and nivolumab in Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment John L. Marshall, MD; Mohamed E. Salem, MD; and Monica Chacha, RN, provide insight on the use of regorafenib in advanced
Side Effects of Later-Line Options in Colorectal Cancer In this segment, Howard S. Hochster, MD; Richard L. Goldberg, MD; and Fadi Braiteh, MD, discuss the use of regorafenib in Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential
More common side effects · bleeding gums · bloody or cloudy urine · blurred vision · cough or hoarseness · coughing up blood · difficult, ReDOS Trial: Optimizing Regorafenib Dosing in metastatic Colorectal Cancer Axel Grothey, MD, Professor of Oncology and Consultant in the Division of Medical Oncology in the Department of Oncology,
Dr. George Demetri Explains the Side Effects Associated With Regorafenib George Demetri, MD, Director of the Ludwig Center and Sarcoma Center at Dana-Farber Cancer Institute and Harvard Medical
Debate 3: Salvage Therapy for mCRC? - Regorafenib Catherine T. Frenette, MD, and Darren S. Sigal, MD, discuss the clinical data surrounding the use of regorafenib for treating
Proactive Side Effect Management With Regorafenib Regorafenib in Colorectal Cancer
There have been tremendous advancements in the multidisciplinary management of GI cancers in the past decade, with a What side effects may I notice from receiving this medication? · Change in voice, hoarseness · Diarrhea · Loss of appetite with weight loss · Nausea · Pain,
Dr Lombardi talks with ecancer at the ESMO 2017 Congress about the randomised, phase II REGOMA trial evaluating regorafenib Andrea Cercek, MD; Zev A. Wainberg, MD; and Tanios Bekaii-Saab, MD, FACP, discuss strategies for proactively managing
Uncommon, but potentially severe side effects include bleeding, poor wound healing, gastrointestinal perforation and fistula, hypertension, Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of
Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, explores results from a Phase II study evaluating the use of regorafenib, Minimizing Side Effects of STIVARGA
Randall F. Holcombe, MD, Associate Director for Clinical Affairs and Director of Gastrointestinal Medical Oncology for the Division Arndt Vogel, MD, and Richard Finn, MD, describe their clinical experience using regorafenib in patients with hepatocellular
Dr. Randall Holcombe Discusses Regorafenib for Metastatic Colorectal Cancer Regorafenib - LiverTox - NCBI Bookshelf
Dr. Axel Grothey on the Side Effect Profile of Regorafenib in Metastatic Colorectal Cancer In this segment, panelists discuss treatment with the multikinase inhibitor regorafenib for patients with metastatic colorectal cancer
Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR Regorafenib Side Effects: Common, Severe, Long Term
Dr. Udit Verma on Regorafenib in Patients With mCRC Dr. Udit Verma on Managing Regorafenib Side Effects in CRC
Regorafenib Tablets: Uses & Side Effects Dr. Lenz on Choosing Between Regorafenib and TAS-102 in CRC Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea outlines the Phase II RENOBATE (NCT04310709)
Treatment Response and Side Effects with Regorafenib Clinical Experience with Regorafenib in HCC Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and
Dr. Bekaii-Saab on TAS-102 and Regorafenib in mCRC The most common and/or important AEs associated with regorafenib were considered to be hand–foot skin reaction, rash or desquamation, stomatitis, diarrhea,
Regorafenib belongs to a group of targeted therapy drugs called cancer growth inhibitors. It is best to read the information about this drug with our general Optimizing Treatment With Regorafenib in Metastic Colorectal Cancer
Dr. Finn on the Promise of Regorafenib for the Treatment of HCC Dr. Sherman on the Role of Regorafenib in Liver Cancer Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in Regorafenib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: · tiredness · weakness · loss of
Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that Clinical Use of Regorafenib in mHCC
Prevention and management of adverse events related to regorafenib Regorafenib as a treatment for GIST (Gastrointestinal Stromal Tumour) patients
Heinz-Josef Lenz, MD, FACP, discusses factors to consider when choosing between regorafenib and trifluridine/tipiracil in the Dr. Finn on Tivantinib and Regorafenib for the Treatment of Liver Cancer
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses optimal dosage for Stivarga Alfredo Carrato, MD, PhD, Ramon y Cajal University Hospital, Madrid, Spain, discusses recently approved treatments for Regorafenib + nivolumab in MMR proficient advanced CRC
Role of the Multikinase Inhibitor Regorafenib in Metastatic Colorectal Cancer Lenz: Stivarga (regorafenib) Treatment, Dosing Strategies Recently, doctors are considering a new dosing strategy for STIVARGA®
Regorafenib in management of colorectal cancer – Video abstract [ID 88825] Cathy Eng, MD, and Jessica Mitchell, RN, CNP, MPH, discuss the management of side effects associated with regorafenib as a
Experts explore side effect management and dose reduction strategies with the multikinase inhibitor regorafenib as a treatment for Dr. Axel Grothey on the Time Course of Regorafenib-Associated Adverse Events
Metastatic colorectal cancer: trifluridine/tiripacil or regorafenib? Dr George Demetri discusses a new drug, Regorafenib, and his research about its effectiveness. Watch the full video here:
Panelists John Marshall, MD; Alan P. Venook, MD; Johanna Bendell, MD; and Tanios Bekaii-Saab, MD, describe their clinical Dr. O'Connor on Real-World Results With Regorafenib in mCRC Regorafenib in Colorectal Cancer: Optimizing the Dose
Colorectal Cancer: Patient Follow-Up with Regorafenib Starting Dose and Side Effects With Regorafenib in mCRC
RENOBATE: investigating regorafenib plus nivolumab as 1st-line therapy for unresectable HCC Debate: Salvage therapy for mCRC? - TAS-102 followed by regorafenib It's crucial to proactively manage side effects with regorafenib in patients with metastatic colorectal cancer, says Dialecti Voudouris
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center discusses Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC
Regorafenib versus lomustine for relapsed glioblastoma Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies Regorafenib (Stivarga) | Cancer information | Cancer Research UK
Practitioners require an understanding of side effects for commonplace treatment options in colorectal cancer. Karon Martyn, MSN Colorectal Cancer: Regorafenib Patient Selection and Dosing Practical Advice for Using Regorafenib
Dr. Heinz-Josef Lenz discusses use and dosing strategies of stivarga (regorafenib) in the treatment of colon cancer at the 2015 The common side effects of oral treatment (sorafenib, lenvatinib, regorafenib or cabozantinib) for advance HCC are fatigue, Cathy Eng, MD, addresses best practices for dose reductions as part of the management of early toxicities experienced by many